Trial Profile
Safety and Efficacy of Tolvaptan (TLV) in Korean patients with the syndrome of inappropriate secretion of antidiuretic hormone (SIADH)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Apr 2018
Price :
$35
*
At a glance
- Drugs Tolvaptan (Primary)
- Indications Hyponatraemia
- Focus Therapeutic Use
- 12 Apr 2018 New trial record
- 09 Apr 2018 Primary endpoint (The average serum sodium concentrations on days 18) has not been met, according to results published in the Journal of Korean Medical Science.
- 09 Apr 2018 Primary endpoint (The average serum sodium concentrations on days 0 and 4) has been met, according to results published in the Journal of Korean Medical Science.